⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

January 14, 2019Future OncologyOpen Access

A Phase II Study of the Safety and Efficacy of Lenvatinib in Patients with Advanced Thyroid Cancer

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

clinicaltrials.gov NCT01728623.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Takahashi et al. (2019) studied this question.

synapsesocial.com/papers/69d7bf43319e71454dbed85a https://doi.org/10.2217/fon-2018-0557

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT TrialRCT · 2017 · 51 citations
2Prognostic Factors and Treatment Outcomes for Anaplastic Thyroid Carcinoma: ATC Research Consortium of Japan Cohort Study of 677 PatientsPrognostic Study · 2012 · 263 citations
3E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibitionOriginal Research · 2007 · 557 citations
4The prognostic value of neutrophil–lymphocyte ratio is superior to derived neutrophil–lymphocyte ratio in advanced gastric cancer treated with preoperative chemotherapy and sequential R0 resection: a 5-year follow-upOriginal Research · 2017 · 22 citations
5Long-Term Outcome of 444 Patients with Distant Metastases from Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of Radioiodine TherapyPrognostic Study · 2006 · 1,697 citations